Telaprevir‐based treatment effects on hepatitis C virus in liver and blood
Andrew H. Talal, Rositsa B. Dimova, Eileen Z. Zhang, Min Jiang, Marina S. Penney, James C. Sullivan, Martyn C. Botfield, Ananthsrinivas Chakilam, Rishikesh Sawant, Christine M. Cervini, Marija Zeremski, Ira M. Jacobson, Ann D. Kwong – 8 May 2014 – Understanding hepatitis C virus (HCV) replication has been limited by access to serial samples of liver, the primary site of viral replication. Our understanding of how HCV replicates and develops drug‐resistant variants in the liver is limited.